{
  "id": "R44032",
  "type": "CRS Report",
  "typeId": "REPORTS",
  "number": "R44032",
  "active": true,
  "source": "EveryCRSReport.com",
  "versions": [
    {
      "source": "EveryCRSReport.com",
      "id": 441259,
      "date": "2015-05-01",
      "retrieved": "2016-04-06T19:07:52.639048",
      "title": "Patents and Regulatory Exclusivities: Issues in Pharmaceutical Innovation and Competition",
      "summary": "Patents and regulatory exclusivities have each been the subject of congressional interest in recent years. Patents, which are administered by the U.S. Patent and Trademark Office (USPTO), allow for a uniform 20-year term of protection for a variety of inventions. In contrast, regulatory exclusivities apply to drugs and biologic medicines regulated by the Food and Drug Administration (FDA). Federal legislation establishes a complex range of regulatory exclusivities applicable to, among other subjects, new chemical entities, orphan drugs, and generic drugs. In general, these intellectual property rights require the FDA to protect an approved drug from competing applications for a set period of time.\nPatents and regulatory exclusivities each create intellectual property rights for their proprietors, but operate through distinct mechanisms. Patents must be enforced through litigation in federal court and may be invalidated during judicial proceedings. In contrast, the FDA ordinarily maintains regulatory exclusivities through agency procedures, without the intervention of the rights holder. Unlike patents, regulatory exclusivities may restrict the sale of public domain medicines. And although patents traditionally provided a longer term of protection, more recently enacted regulatory exclusivities tend to have more comparable durations.\nThe patent system has traditionally served as the primary innovation incentive for new medicines. But recent legislative trends may elevate the regulatory exclusivity from a supplemental protection scheme to the primary driver of innovation within the pharmaceutical industry. For example, the Generating Antibiotics Incentives Now (GAIN) Act and the Biologics Price Competition and Innovation Act created regulatory exclusivities of 10 to 12 years, respectively, for certain products. \nLegislation introduced most recently before the 113th Congress, the MODDERN Cures Act, H.R. 3116, would have continued to expand the role of regulatory exclusivities. That unenacted legislation would have effectively allowed brand-name pharmaceutical firms, in certain circumstances, to exchange their patents for a 15-year period of regulatory exclusivity. While proponents of the legislation believe it would provide a more certain and effective innovation incentive for the pharmaceutical industry, others assert that it significantly expands intellectual property rights and represents a windfall for the brand-name drug industry. These proposals have been placed before the 114th Congress in the form of a discussion draft of the 21st Century Cures Act.\nCongress has several options as it considers the relationship between patents and regulatory exclusivities. If the current situation is deemed satisfactory, then no action need be taken. Other options include rationalizing the various terms of protection and scope of rights that regulatory exclusivities provide. Congress may also consider providing distinct names for the regulatory exclusivities and ensuring that these rights do not remove safe and effective medicines from the public domain.",
      "type": "CRS Report",
      "typeId": "REPORTS",
      "active": true,
      "formats": [
        {
          "format": "HTML",
          "encoding": "utf-8",
          "url": "http://www.crs.gov/Reports/R44032",
          "sha1": "2b1d573b730baf423d6e555eefb02a7d324bcb8c",
          "filename": "files/20150501_R44032_2b1d573b730baf423d6e555eefb02a7d324bcb8c.html",
          "images": null
        },
        {
          "format": "PDF",
          "encoding": null,
          "url": "http://www.crs.gov/Reports/pdf/R44032",
          "sha1": "ce6d820c84f43a1da8db3e4b7444e1788ff4c4e3",
          "filename": "files/20150501_R44032_ce6d820c84f43a1da8db3e4b7444e1788ff4c4e3.pdf",
          "images": null
        }
      ],
      "topics": [
        {
          "source": "IBCList",
          "id": 2688,
          "name": "Intellectual Property Rights"
        }
      ]
    }
  ],
  "topics": []
}